Bibliographic Details
| Title: |
Induction therapy in heart transplantation: A systematic review and network meta‐analysis for developing evidence‐based recommendations. |
| Authors: |
Kugathasan, Lakshmi, Rayner, Daniel G, Wang, Sabrina Mianchen, Rodenas‐Alesina, Eduardo, Orchanian‐Cheff, Ani, Stehlik, Josef, Gustafsson, Finn, Greig, Douglas, McDonald, Michael, Bertolotti, Alejandro Mario, Demas‐Clarke, Penny, Kozuszko, Stella, Guyatt, Gordon, Foroutan, Farid, Alba, Ana Carolina |
| Source: |
Clinical Transplantation; May2024, Vol. 38 Issue 5, p1-16, 16p |
| Subject Terms: |
HEART transplantation, BASILIXIMAB, SCIENTIFIC observation, CHIMERIC proteins |
| Abstract: |
Introduction: Induction therapy (IT) utility in heart transplantation (HT) remains contested. Commissioned by a clinical‐practice guidelines panel to evaluate the effectiveness and safety of IT in adult HT patients, we conducted this systematic review and network meta‐analysis (NMA). Methods: We searched for studies from January 2000 to October 2022, reporting on the use of any IT agent in adult HT patients. Based on patient‐important outcomes, we performed frequentist NMAs separately for RCTs and observational studies with adjusted analyses, and assessed the certainty of evidence using the GRADE framework. Results: From 5156 publications identified, we included 7 RCTs and 12 observational studies, and report on two contemporarily‐used IT agents—basiliximab and rATG. The RCTs provide only very low certainty evidence and was uninformative of the effect of the two agents versus no IT or one another. With low certainty in the evidence from observational studies, basiliximab may increase 30‐day (OR 1.13; 95% CI 1.06–1.20) and 1‐year (OR 1.11; 95% CI 1.02–1.22) mortality compared to no IT. With low certainty from observational studies, rATG may decrease 5‐year cardiac allograft vasculopathy (OR.82; 95% CI.74–.90) compared to no IT, as well as 30‐day (OR.85; 95% CI.80–.92), 1‐year (OR.87; 95% CI.79–.96), and overall (HR.84; 95% CI.76–.93) mortality compared to basiliximab. Conclusion: With low and very low certainty in the synthetized evidence, these NMAs suggest possible superiority of rATG compared to basiliximab, but do not provide compelling evidence for the routine use of these agents in HT recipients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Transplantation is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
